• Anticancer research · Jul 2020

    Multicenter Study Observational Study

    GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.

    • FrÉdÉric Selle, Pierre-Etienne Heudel, Anne-Claire Hardy-Bessard, Astrid Pozet, Jerome Meunier, Laurence Gladieff, Jean-Pierre Lotz, Magali Provansal, Paule Augereau, Dominique Berton, Nathalie Bonichon-Lamichhane, Hubert Orfeuvre, Patricia Pautier, Elsa Kalbacher, Yousef Tazi, and Dominique Spaeth.
    • Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France fselle@hopital-dcss.org.
    • Anticancer Res. 2020 Jul 1; 40 (7): 3939-3945.

    BackgroundTrabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.Patients And MethodsPatients with ROC after at least one platinum-based regimen received 1.1 mg/m2 trabectedin plus 30 mg/m2 PLD every 3 weeks. Efficacy and safety were evaluated in subgroups according to platinum-free interval [6-12 versus ≥12 months (partially or fully platinum sensitive, respectively)].ResultsRecurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups.ConclusionTrabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…